Omnicell, Inc. (NASDAQ:OMCL) Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 93.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,450,416 shares of the company’s stock after acquiring an additional 699,925 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 3.13% of Omnicell worth $64,573,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of OMCL. The Manufacturers Life Insurance Company grew its holdings in Omnicell by 6.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,459 shares of the company’s stock valued at $635,000 after purchasing an additional 1,360 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the last quarter. Creative Planning increased its holdings in shares of Omnicell by 23.1% during the 3rd quarter. Creative Planning now owns 11,667 shares of the company’s stock worth $509,000 after buying an additional 2,188 shares during the last quarter. Accurate Wealth Management LLC raised its position in shares of Omnicell by 14.8% in the 3rd quarter. Accurate Wealth Management LLC now owns 21,260 shares of the company’s stock worth $901,000 after buying an additional 2,746 shares during the period. Finally, Everence Capital Management Inc. acquired a new position in Omnicell in the third quarter valued at $249,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Insider Buying and Selling

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.64% of the company’s stock.

Omnicell Trading Up 1.9 %

OMCL opened at $40.16 on Monday. The firm’s 50 day moving average is $44.21 and its 200-day moving average is $43.38. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74. The company has a quick ratio of 0.95, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.86 billion, a P/E ratio of 148.75, a P/E/G ratio of 26.98 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Analysts expect that Omnicell, Inc. will post 1.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on OMCL shares. JPMorgan Chase & Co. upped their price target on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Barclays increased their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Bank of America decreased their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Benchmark reissued a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. Finally, StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $52.33.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.